Figure 1.
Figure 1. Cumulative incidence of EMR (<10% IS) following the initiation of generic or brand-name imatinib.

Cumulative incidence of EMR (<10% IS) following the initiation of generic or brand-name imatinib.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal